BioCentury | Mar 22, 2016
Financial News

Atlantic raises $24M venture round

...U.K.) raised $24 million in a venture round from Lorin Johnson and other founders of Salix Pharmaceuticals Inc....
BioCentury | Feb 8, 2016
Company News

Valeant Pharmaceuticals, Express Scripts sales and marketing update

...Glumetza from Depomed Inc. (NASDAQ:DEPO, Menlo Park, Calif.) in the U.S. through its acquisition of Salix Pharmaceuticals Inc....
BioCentury | Feb 16, 2015
Company News

Napo, Salix Pharmaceuticals Inc. gastrointestinal news

...conductance regulator (CFTR) and calcium-activated chloride channel . Napo Pharmaceuticals Inc. , San Francisco, Calif. Salix Pharmaceuticals Inc....
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...Inc. (NASDAQ:OREX)/Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) FDA approves Contrave naltrexone/bupropion for obesity Pharming Group N.V. (Euronext:PHARM)/Salix Pharmaceuticals Inc....
BioCentury | Jul 21, 2014
Clinical News

Rhucin regulatory update

...Pharming to treat acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Partner Salix Pharmaceuticals Inc....
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Discerning optimism

...race to get deals done. Indeed, the latest tax-inversion deal was announced last week, when Salix Pharmaceuticals Inc....
...Basel, Switzerland Parnell Pharmaceuticals Holdings Ltd. (NASDAQ:PARN), Alexandria, Australia Pfizer Inc. (NYSE:PFE), New York, N.Y. Salix Pharmaceuticals Inc....
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Summer lull

...NASDAQ:PCYC) Imbruvica ibrutinib CLL and small lymphocytic leukemia (SLL) PDUFA date 10/7/14 Pharming Group N.V. (Euronext:PHARM)/Salix Pharmaceuticals Inc....
BioCentury | Jul 14, 2014
Finance

Highlights of weekly biotech stock moves

...plan to start Phase III testing of dupilumab to treat moderate to severe atopic dermatitis. Salix Pharmaceuticals Inc....
BioCentury | Jul 2, 2014
Clinical News

Salix reports Phase III IBS-D data

Salix Pharmaceuticals Inc. (NASDAQ:SLXP) said Xifaxan rifaximin met the composite primary endpoint in a Phase III trial in about 800 patients with irritable bowel syndrome with diarrhea (IBS-D). The endpoint was a greater proportion of...
BioCentury | Jun 16, 2014
Clinical News

Relistor methylnaltrexone regulatory update

...to the subcutaneous formulation (see BioCentury, Feb. 14, 2011). Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Tarrytown, N.Y. Salix Pharmaceuticals Inc....
Items per page:
1 - 10 of 94
BioCentury | Mar 22, 2016
Financial News

Atlantic raises $24M venture round

...U.K.) raised $24 million in a venture round from Lorin Johnson and other founders of Salix Pharmaceuticals Inc....
BioCentury | Feb 8, 2016
Company News

Valeant Pharmaceuticals, Express Scripts sales and marketing update

...Glumetza from Depomed Inc. (NASDAQ:DEPO, Menlo Park, Calif.) in the U.S. through its acquisition of Salix Pharmaceuticals Inc....
BioCentury | Feb 16, 2015
Company News

Napo, Salix Pharmaceuticals Inc. gastrointestinal news

...conductance regulator (CFTR) and calcium-activated chloride channel . Napo Pharmaceuticals Inc. , San Francisco, Calif. Salix Pharmaceuticals Inc....
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...Inc. (NASDAQ:OREX)/Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) FDA approves Contrave naltrexone/bupropion for obesity Pharming Group N.V. (Euronext:PHARM)/Salix Pharmaceuticals Inc....
BioCentury | Jul 21, 2014
Clinical News

Rhucin regulatory update

...Pharming to treat acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Partner Salix Pharmaceuticals Inc....
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Discerning optimism

...race to get deals done. Indeed, the latest tax-inversion deal was announced last week, when Salix Pharmaceuticals Inc....
...Basel, Switzerland Parnell Pharmaceuticals Holdings Ltd. (NASDAQ:PARN), Alexandria, Australia Pfizer Inc. (NYSE:PFE), New York, N.Y. Salix Pharmaceuticals Inc....
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Summer lull

...NASDAQ:PCYC) Imbruvica ibrutinib CLL and small lymphocytic leukemia (SLL) PDUFA date 10/7/14 Pharming Group N.V. (Euronext:PHARM)/Salix Pharmaceuticals Inc....
BioCentury | Jul 14, 2014
Finance

Highlights of weekly biotech stock moves

...plan to start Phase III testing of dupilumab to treat moderate to severe atopic dermatitis. Salix Pharmaceuticals Inc....
BioCentury | Jul 2, 2014
Clinical News

Salix reports Phase III IBS-D data

Salix Pharmaceuticals Inc. (NASDAQ:SLXP) said Xifaxan rifaximin met the composite primary endpoint in a Phase III trial in about 800 patients with irritable bowel syndrome with diarrhea (IBS-D). The endpoint was a greater proportion of...
BioCentury | Jun 16, 2014
Clinical News

Relistor methylnaltrexone regulatory update

...to the subcutaneous formulation (see BioCentury, Feb. 14, 2011). Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Tarrytown, N.Y. Salix Pharmaceuticals Inc....
Items per page:
1 - 10 of 94